Yuyu Pharma, Inc. (000227.KS)
KRW 9750.0
(-0.41%)
KRW 9750.0
(-0.41%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 8.8 Billion KRW | -34.5% |
| 2022 | 13.43 Billion KRW | 221.09% |
| 2021 | -11.09 Billion KRW | -2875.92% |
| 2020 | -372.89 Million KRW | -487.12% |
| 2019 | 96.32 Million KRW | -60.57% |
| 2018 | 244.27 Million KRW | 162.16% |
| 2017 | -392.96 Million KRW | 80.4% |
| 2016 | -2 Billion KRW | -126.35% |
| 2015 | 7.61 Billion KRW | 224.99% |
| 2014 | -6.08 Billion KRW | -1373.52% |
| 2013 | 478.13 Million KRW | 131.7% |
| 2012 | -1.5 Billion KRW | -154.88% |
| 2011 | 2.74 Billion KRW | -61.81% |
| 2010 | 7.19 Billion KRW | -39.92% |
| 2009 | 11.98 Billion KRW | -51.12% |
| 2008 | 24.51 Billion KRW | -16.91% |
| 2007 | 29.5 Billion KRW | -22.21% |
| 2006 | 37.92 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 7.43 Billion KRW | -15.55% |
| 2024 Q2 | 439.06 Million KRW | -94.09% |
| 2023 FY | 8.8 Billion KRW | -34.5% |
| 2023 Q3 | 25.25 Billion KRW | 20.83% |
| 2023 Q2 | 20.9 Billion KRW | 27.9% |
| 2023 Q4 | 8.8 Billion KRW | -65.15% |
| 2023 Q1 | 16.34 Billion KRW | 21.61% |
| 2022 Q4 | 13.43 Billion KRW | 289.89% |
| 2022 FY | 13.43 Billion KRW | 221.09% |
| 2022 Q3 | 3.44 Billion KRW | 272.92% |
| 2022 Q2 | -1.99 Billion KRW | 78.91% |
| 2022 Q1 | -9.45 Billion KRW | 14.84% |
| 2021 FY | -11.09 Billion KRW | -2875.92% |
| 2021 Q2 | -15.65 Billion KRW | -3865.74% |
| 2021 Q3 | -16.19 Billion KRW | -3.45% |
| 2021 Q4 | -11.09 Billion KRW | 31.46% |
| 2021 Q1 | 415.61 Million KRW | 211.46% |
| 2020 Q2 | 9.25 Billion KRW | 84.65% |
| 2020 FY | -372.89 Million KRW | -487.12% |
| 2020 Q3 | 5.4 Billion KRW | -41.54% |
| 2020 Q1 | 5.01 Billion KRW | 5101.61% |
| 2020 Q4 | -372.89 Million KRW | -106.89% |
| 2019 Q4 | 96.32 Million KRW | 372.11% |
| 2019 Q3 | -35.39 Million KRW | 98.87% |
| 2019 FY | 96.32 Million KRW | -60.57% |
| 2019 Q1 | 7.5 Billion KRW | 2972.45% |
| 2019 Q2 | -3.12 Billion KRW | -141.7% |
| 2018 Q2 | -2.07 Billion KRW | -477.08% |
| 2018 FY | 244.27 Million KRW | 162.16% |
| 2018 Q4 | 244.27 Million KRW | -94.61% |
| 2018 Q3 | 4.52 Billion KRW | 318.04% |
| 2018 Q1 | 550.9 Million KRW | 0.0% |
| 2017 FY | -392.96 Million KRW | 80.4% |
| 2017 Q1 | -2 Billion KRW | 44.56% |
| 2017 Q2 | -1.58 Billion KRW | 20.93% |
| 2017 Q3 | -312.48 Million KRW | 80.29% |
| 2016 Q4 | -3.61 Billion KRW | -13609.84% |
| 2016 Q3 | 26.77 Million KRW | -99.17% |
| 2016 Q2 | 3.21 Billion KRW | -57.78% |
| 2016 Q1 | 7.61 Billion KRW | -14.27% |
| 2016 FY | -2 Billion KRW | -126.35% |
| 2015 Q1 | -6.08 Billion KRW | -153.53% |
| 2015 FY | 7.61 Billion KRW | 224.99% |
| 2015 Q4 | 8.87 Billion KRW | 532.52% |
| 2015 Q3 | 1.4 Billion KRW | 167.0% |
| 2015 Q2 | -2.09 Billion KRW | 65.6% |
| 2014 Q4 | -2.4 Billion KRW | -151.4% |
| 2014 Q3 | -955.31 Million KRW | -173.2% |
| 2014 Q2 | 1.3 Billion KRW | 172.97% |
| 2014 Q1 | 478.13 Million KRW | -62.22% |
| 2014 FY | -6.08 Billion KRW | -1373.52% |
| 2013 Q3 | -668.63 Million KRW | 46.16% |
| 2013 Q2 | -1.24 Billion KRW | 17.68% |
| 2013 FY | 478.13 Million KRW | 131.7% |
| 2013 Q1 | -1.5 Billion KRW | 0.0% |
| 2013 Q4 | 1.26 Billion KRW | 289.27% |
| 2012 FY | -1.5 Billion KRW | -154.88% |
| 2011 Q4 | 3.36 Billion KRW | -24.45% |
| 2011 Q2 | 6.33 Billion KRW | -11.98% |
| 2011 Q3 | 4.44 Billion KRW | -29.78% |
| 2011 Q1 | 7.19 Billion KRW | -18.78% |
| 2011 FY | 2.74 Billion KRW | -61.81% |
| 2010 Q3 | 9.57 Billion KRW | -11.26% |
| 2010 Q2 | 10.79 Billion KRW | -9.93% |
| 2010 Q1 | 11.98 Billion KRW | -28.54% |
| 2010 Q4 | 8.86 Billion KRW | -7.45% |
| 2010 FY | 7.19 Billion KRW | -39.92% |
| 2009 Q4 | 16.76 Billion KRW | -1.63% |
| 2009 Q2 | 21.29 Billion KRW | -13.13% |
| 2009 Q3 | 17.04 Billion KRW | -19.95% |
| 2009 FY | 11.98 Billion KRW | -51.12% |
| 2009 Q1 | 24.51 Billion KRW | -21.25% |
| 2008 Q3 | 31.17 Billion KRW | 23.35% |
| 2008 Q1 | 29.5 Billion KRW | -9.88% |
| 2008 FY | 24.51 Billion KRW | -16.91% |
| 2008 Q4 | 31.12 Billion KRW | -0.15% |
| 2008 Q2 | 25.27 Billion KRW | -14.33% |
| 2007 Q2 | 29.92 Billion KRW | 0.0% |
| 2007 Q4 | 32.73 Billion KRW | 1.04% |
| 2007 Q3 | 32.39 Billion KRW | 8.25% |
| 2007 FY | 29.5 Billion KRW | -22.21% |
| 2006 FY | 37.92 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 98.461% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 97.169% |
| HANDOK Inc. | 283.45 Billion KRW | 96.895% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | 56.147% |
| Yuhan Corporation | -69.18 Billion KRW | 112.723% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 95.462% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 338.814% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 98.3% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 127.141% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 88.368% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 76.105% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 89.333% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | 64.943% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 0.0% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 105.507% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 95.62% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 94.851% |
| JW Holdings Corporation | 480.68 Billion KRW | 98.169% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 94.652% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -7389.275% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 94.298% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -274.354% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | 61.732% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 94.969% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 83.064% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 0.0% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 94.439% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 97.542% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 94.298% |
| Yuhan Corporation | -69.18 Billion KRW | 112.723% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 93.527% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 85.249% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 97.949% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 94.298% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 92.427% |
| Korea United Pharm Inc. | 16.42 Billion KRW | 46.41% |
| CKD Bio Corp. | 143.29 Billion KRW | 93.857% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 92.416% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 136.582% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 119.677% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -274.354% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 97.918% |
| Boryung Corporation | 187.72 Billion KRW | 95.311% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 112.253% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 88.368% |
| JW Lifescience Corporation | 26.09 Billion KRW | 66.263% |